

Overdoses with Xylazine and Fentanyl Recorded in Pennsylvania's Overdose Information Network

Manuel Cano, PhD^{*,a} David T. Zhu, MPH,^b Yesenia Aponte-Meléndez, PhD^{c,d} Pedro Mateu-Gelabert, PhD^e Alex S. Bennett, PhD^f

- a. School of Social Work, Arizona State University, 411 N Central Ave, Phoenix, AZ 85004, USA
- b. Medical Scientist Training Program, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23298, USA
- c. CUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Population Health(ISPH), 55 West 125th street, New York, NY 10027,USA
- d. NYU Rory Meyers College of Nursing 433 1st Ave., New York, NY 10010, USA
- e. CUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Population Health(ISPH), 55 West 125th street, New York, NY 10027,USA
- f. School of Global Public Health, New York University, 708 Broadway, New York, NY 10003, USA

*Corresponding author: Manuel Cano, mcanomor@asu.edu, 411 N Central Ave, Phoenix, AZ 85004, USA

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interests: None.

Abstract

Objectives: This descriptive study examined suspected xylazine co-involvement in law enforcement-recorded fentanyl overdoses in Pennsylvania (excluding Philadelphia), focusing on other drug involvement, naloxone administration, and survival.

Methods: We examined data from 10,626 suspected fentanyl-involved overdoses (95 reportedly co-involving xylazine) recorded in the Pennsylvania Overdose Information Network (ODIN), January 2018-July 2024. All measures were based on law enforcement/first-responder assessment/report. We used relative frequencies, Fisher's exact tests, and binomial logistic regression models, comparing overdoses reportedly involving xylazine and fentanyl versus those involving fentanyl but no xylazine.

Results: Several drugs were reported in significantly larger proportions of overdoses in the fentanyl-xylazine group than the fentanyl-no-xylazine group: carfentanil (11.6% vs. 2.2%); other synthetic opioids (20.0% vs. 7.6%); methamphetamine (21.1% vs. 6.9%); and benzodiazepines (6.3% vs. 2.3%). Naloxone was administered in 41.1% of the cases reportedly involving xylazine, vs. 67.5% of the no-xylazine cases; 62.1% of the overdoses with xylazine recorded were fatal, compared to 27.7% of the fentanyl-no-xylazine overdoses. In multivariable regression models (among the suspected fentanyl overdoses recorded in ODIN, adjusting for age, gender, race/ethnicity, year, county, and other drugs reported): suspected xylazine involvement was associated with 65% lower odds of naloxone administration (Adjusted Odds Ratio [AOR] 0.35; 95% Confidence Interval [CI], 0.23-0.56) and 79% lower odds of survival (AOR 0.21; 95% CI, 0.13-0.35).

Conclusions: In this study of law enforcement-recorded fentanyl overdose events in Pennsylvania, excluding Philadelphia: relative to fentanyl-no-xylazine overdoses, higher proportions of xylazine-fentanyl overdoses co-involved other synthetic opioids or methamphetamine, did not receive naloxone at the scene, and were fatal.

Keywords: xylazine; fentanyl; overdose; naloxone; fatality

Overdoses with Xylazine and Fentanyl Recorded in Pennsylvania's Overdose Information Network

Introduction

Xylazine, a veterinary non-opiate sedative and analgesic, is increasingly detected in overdose deaths in the United States (US), usually accompanied by fentanyl (Spencer et al., 2023). Philadelphia, Pennsylvania is considered the earliest epicenter of xylazine-adulterated drugs in the mainland US (Friedman et al., 2022; Zhu, 2023), and xylazine-related overdose deaths have primarily been concentrated in the northeastern US (Spencer et al., 2023). Nonetheless, recent studies suggest that xylazine's presence in illicit drug supplies may be spreading throughout the US as well as other nations (Bradford et al., 2024; Cano et al., 2024; Copeland et al., 2024; Delcher et al., 2024; Friedman et al., 2022, 2024; Thomas et al., 2024; Wu and Austin, 2024).

Although the potential impacts of xylazine on overdose outcomes are unclear (D'Orazio et al., 2023; Hoffman, 2023), polysubstance overdoses co-involving xylazine and fentanyl present additional challenges for clinical management and public health strategies (Gupta et al., 2022). Since xylazine is not an opioid, administration of the opioid overdose reversal agent naloxone does not directly address xylazine's effects (Gupta et al., 2023); however, naloxone is still recommended as a critical tool to save lives in cases of xylazine-related overdose (Gupta et al., 2023; Zagorski et al., 2023; Zhu, 2023) because opioids such as fentanyl are nearly always co-involved (reported in 99% of xylazine-related fatalities nationwide; Spencer et al., 2023).

Most studies on xylazine-involved overdoses focus exclusively on fatal (Johnson et al., 2021; Kariisa et al., 2023; Sibbesen et al., 2023; Spencer et al., 2023) or non-fatal overdoses (German et al., 2024) or clinical samples (Love et al., 2023). Considering that a better

understanding of both fatal and non-fatal overdoses involving xylazine could strengthen prevention and harm reduction efforts, the present study leverages data on both fatal and non-fatal overdoses recorded by law-enforcement/first-responders in Pennsylvania (excluding Philadelphia). This descriptive study examines co-involved drugs, naloxone administration, and survival in fentanyl overdoses with and without xylazine involvement suspected.

Methods

Study Design and Sample

We analyzed publicly available data from the Pennsylvania State Police's Overdose Information Network ([ODIN] Pennsylvania State Police, 2024), a repository compiling overdoses attended by participating law enforcement agencies (or voluntarily reported by other first-responders). ODIN data do not represent all Pennsylvania overdoses or all law enforcement-attended overdoses (not including, for example, overdoses in which 911 was never contacted or in which the responding personnel were not ODIN-reporting agencies or voluntary reporters). Nonetheless, ODIN has been used in prior analyses of Pennsylvania overdoses (e.g., Barboza and Angulski, 2020; Holmes et al., 2022) due to the critical information offered regarding drugs suspected in overdoses, naloxone administration, and overdose survival or fatality.

The study's analytic sample comprised 10,626 suspected fentanyl-involved overdoses, each with a unique victim ID/incident ID combination, and 95 of these overdoses (0.9%) also included xylazine as a suspected drug. In Supplemental Table S1, we summarize the process followed to identify unique records and merge data from the multiple records used to report different drugs involved in the same overdose. Since the Philadelphia Police Department was not included as one of the 752 ODIN-reporting agencies (as of the study date), we limited our study to overdoses outside of Philadelphia County. (This resulted in the exclusion of the 67 [0.6%]

fentanyl-involved overdoses recorded by the only Philadelphia County agencies listed as ODIN reporters: Drexel University Police and Philco). The study data included overdoses recorded between January 1, 2018-July 15, 2024 (from the ODIN dataset updated on July 15, 2024). The study was classified as “exempt” by the Arizona State University Institutional Review Board based on Federal Regulation 45CFR46 (4).

Measures

All measures in ODIN are based on the report of first responders such as law enforcement; drugs “suspected” to be involved in overdoses are determined through methods such as evidence/interviews at the scene or drug field testing (Barboza and Angulski, 2020). In the present study, our exposure of interest was a binary indicator (yes/no) for whether xylazine was recorded as a “suspected” drug. We examined demographics (gender, age category, and race/ethnicity), other drugs suspected (binary indicators for heroin, carfentanil, other synthetic opioids/fentanyl analogs, pharmaceutical opioids, methamphetamine, cocaine/crack, benzodiazepines, and alcohol), and year and county of occurrence. Finally, we focused on two outcome measures: 1) whether naloxone was administered at the scene (yes/no); and 2) whether the individual survived (yes/no, as reported in ODIN by the responding agency).

Analyses

To summarize characteristics of suspected fentanyl overdoses with vs. without xylazine involved, we calculated descriptive statistics and used Fisher’s exact tests for comparisons (due to small numbers in some categories). Next, binomial logistic regression models tested associations between x) *suspected xylazine involvement* (in fentanyl overdoses recorded in ODIN) and two separate outcomes, y_1) administration of *naloxone*, and y_2) *surviving* the overdose, adjusting for gender, age, race/ethnicity, county of occurrence, year, and other

“suspected” drugs involved (heroin, carfentanil, other synthetic opioids/fentanyl analogs, pharmaceutical opioids, methamphetamine, cocaine/crack, benzodiazepines, alcohol). Results were expressed using adjusted odds ratios (AORs) and 95% Confidence Intervals (CIs), as well as average marginal effects (AMEs). Analyses were completed in Stata/MP 18.5, and all regression models used listwise deletion for missing data (with a maximum of 7.9% missing/unknown on all measures combined). Supplemental analyses: a) changed the analytic sample from suspected fentanyl overdoses only to overdoses involving any type of opioid; and b) limited the timeframe to 2022-2024, since xylazine was rarely reported in ODIN prior to 2022.

Results

As reflected in Table 1, ODIN-recorded fentanyl overdoses, both with (n=95) and without (n=10,531) xylazine reported, were concentrated among men, in ages 30-39, and among Non-Hispanic (NH) White individuals, with no statistically significant demographic differences observed. As detailed in Supplemental Table S2, the highest numbers of both fentanyl-xylazine and fentanyl-no-xylazine ODIN overdose events were recorded in Allegheny and Montgomery counties. All of the suspected xylazine-fentanyl overdoses occurred during or after 2021, with the majority occurring after 2021 (Supplemental Table S2).

As depicted in Figure 1 (and detailed in Supplemental Table S3), several drugs were reported in significantly larger proportions of overdoses in the suspected xylazine group than the no-xylazine group: carfentanil (11.6% vs. 2.2%; $p<0.001$); other synthetic opioids/fentanyl analogs (20.0% vs. 7.6%; $p<0.001$); methamphetamine (21.1% vs. 6.9%; $p<0.001$); and benzodiazepines (6.3% vs. 2.3%; $p=0.022$). Conversely, heroin was reported in less than half (44.2%) of the overdoses in the xylazine group versus more than two thirds (67.6%) in the no-xylazine group ($p<0.001$). Naloxone was administered in 41.1% of the cases reportedly

involving xylazine, versus 67.5% of the no-xylazine cases ($p < 0.001$), and death was the outcome of 62.1% of the cases with xylazine recorded, compared to 27.7% of the no-xylazine cases ($p < 0.001$).

In multivariable regression models (Table 2), even after adjusting for age, gender, race/ethnicity, year, county, and suspected involvement of other drugs, suspected xylazine involvement was associated with 65% lower odds of naloxone administration (AOR 0.35; 95% CI, 0.23-0.56; or 21 percent lower probability) and 79% lower odds of survival (AOR 0.21; 95% CI, 0.13-0.35; or 28 percent lower probability) among the suspected fentanyl overdoses recorded in ODIN. Regression results from sensitivity analyses (Table 3) were similar when broadening the analytic sample to overdoses involving any type of opioid (instead of fentanyl specifically) and when restricting the analysis time frame to the years xylazine was most frequently reported in ODIN, 2022-2024.

Discussion

Study findings highlight several differences between suspected fentanyl overdoses with, versus without, xylazine in the Pennsylvania ODIN (excluding Philadelphia County). First, compared to fentanyl-involved overdoses without xylazine suspected, significantly higher proportions of overdoses with xylazine suspected also reportedly involved fentanyl analogs/other synthetic opioids, methamphetamine, and benzodiazepines. This finding aligns with results of studies documenting stimulant or benzodiazepine co-involvement in xylazine-fentanyl deaths and larger numbers of co-involved drugs among deaths involving xylazine than those not involving xylazine (Bradford et al., 2024; Sibbesen et al., 2023).

Second, among ODIN-recorded fentanyl overdose deaths, suspected xylazine co-involvement was associated with lower probabilities of naloxone administration and survival,

even after adjusting for other drug co-involvement, demographics, county, and year. In an analysis of *fatal* overdoses in 20 US states and the District of Columbia, naloxone administration was reported in similar proportions of fentanyl-related overdose deaths with and without xylazine detected (Kariisa et al., 2023). The contrast between this prior study's findings and the results of the present study may possibly reflect differences in study settings as well as the inclusion of both fatal and nonfatal overdoses in the present study.

Although not examined in the present study, differences in naloxone administration rates based on suspected xylazine co-involvement may plausibly reflect factors such as: uncertainty regarding how to respond in light of distinctions between xylazine-associated sedation versus opioid-induced respiratory depression; elevated stigma surrounding xylazine (Bowles et al., 2024); and varying levels of access to naloxone or overdose education based on local area rurality or resource levels. All of the cases included in the present study reportedly involved fentanyl, yet it is not clear in what quantity and whether all cases evidenced opioid-induced respiratory depression that would specifically indicate a need for naloxone. Moreover, in some portion of ODIN cases, naloxone might not have been administered because the person was already deceased by the time first responders arrived.

Limitations

ODIN data are not inclusive of, nor representative of, all law-enforcement-attended overdoses in Pennsylvania. Moreover, overdoses in Philadelphia (the largest county, one with a particularly diverse population, and often regarded the epicenter of xylazine; Friedman et al., 2022) were not included in the study's analysis, as the Philadelphia Police Department was not an ODIN reporting agency at the time of the study. All ODIN measures, including drug involvement, are based on first-responder assessment/report. ODIN reporters use a variety of

methods to identify suspected drugs involved (including drug field testing, interviews with those at the scene, and investigation of drugs and paraphernalia present; Barboza and Angulski, 2020), and it is plausible that fatal overdoses may receive more investigative resources than non-fatal events; it is also possible that law enforcement may be more likely to suspect and report more drugs in fatal, relative to non-fatal, cases.

ODIN data may also possibly over-report historically common drugs such as heroin (as drug checking data indicate that what is sold as heroin has largely been replaced by fentanyl; The Center for Forensic Science Research & Education, 2023) while under-identifying emerging drugs such as xylazine. It is unclear to what extent this potential underreporting of xylazine compares to the level of xylazine underreporting in mortality data and nonfatal overdose surveillance data due to limited testing (Korona-Bailey et al., 2023; Spencer et al., 2023) or the level of discrepancy between residue xylazine test strip results and full toxicology testing (Thompson et al., 2024). Researchers have also noted a lack of standardized guidelines specifying quantities or signs that distinguish between an overdose in which xylazine was detected versus an overdose in which xylazine specifically contributed to the drug toxicity (Kariisa et al., 2023). Finally, many unmeasured factors (e.g., underlying health status and opioid tolerance levels, quantity of drugs consumed, and resources and procedures of each local area's emergency system) may contribute to the outcomes examined in the study; some of these factors (e.g., local first responder procedures and resources) may also impact the measurement of the predictor (that is, the processes used to assess whether or not xylazine was involved in the overdose).

Conclusions

The present study did not test causal relationships, but rather provided preliminary evidence of lower naloxone administration and less survival in suspected xylazine-fentanyl-involved overdoses recorded by ODIN-participating law enforcement/first-responders in Pennsylvania (outside of Philadelphia). The potential role of xylazine in overdose outcomes is unclear (D’Orazio et al., 2023; Hoffman, 2023); research with rodents suggests that xylazine exposure may worsen risk of fatality from opioid overdose (Choi et al., 2023), while an analysis of opioid overdoses treated in nine US emergency departments documented less severe outcomes (less cardiac arrest and coma) in xylazine-positive, versus xylazine-negative, opioid overdose patients (Love et al., 2023).

Although further research is needed to better understand xylazine-fentanyl-involved overdoses, findings of the present study underscore the importance of expanding access to lifesaving medications such as naloxone. While naloxone does not directly reverse the effects of xylazine, it remains effective in reversing the effects of the fentanyl with which xylazine is often mixed (Kariisa et al., 2023). Public health and harm reduction programs play a vital role in disseminating evidence-based information on the local drug supply, naloxone, and rescue breathing and other lifesaving care for individuals with suspected overdoses involving fentanyl and xylazine. Study findings also support the importance of making low-threshold harm reduction and drug checking services widely available to people who use drugs and equipping first responders with naloxone and training regarding recognizing and managing the distinct challenges associated with xylazine exposure and polysubstance overdoses.

Acknowledgements: None

References

- Barboza, G. E., Angulski, K., 2020. A descriptive study of racial and ethnic differences of drug overdoses and naloxone administration in Pennsylvania. *Int J Drug Policy*. 78, 102718. <https://doi.org/10.1016/j.drugpo.2020.102718>
- Bowles, J. M., Copulsky, E. C., Reed, M. K., 2024. Media framing xylazine as a “zombie drug” is amplifying stigma onto people who use drugs. *Int J Drug Policy*. 125, 104338. <https://doi.org/10.1016/j.drugpo.2024.104338>
- Bradford, W., Figgatt, M., Scott, K. S., Marshall, S., Eaton, E. F., Dye, D. W., 2024. Xylazine co-occurrence with illicit fentanyl is a growing threat in the Deep South: A retrospective study of decedent data. *Harm Reduct J*. 21, (46). <https://doi.org/10.1186/s12954-024-00959-2>
- Cano, M., Daniulaityte, R., Marsiglia, F., 2024. Xylazine in overdose deaths and forensic drug reports in US States, 2019-2022. *JAMA Netw Open*. 7, (1). [doi:10.1001/jamanetworkopen.2023.50630](https://doi.org/10.1001/jamanetworkopen.2023.50630)
- The Center for Forensic Science Research & Education, 2023. Drug checking. <https://www.cfsre.org/nps-discovery/drug-checking>
- Choi, S., Irwin, M. R., Kiyatkin, E. A., 2023. Xylazine effects on opioid-induced brain hypoxia. *Psychopharmacology (Berl)*. 240 (7). <https://doi.org/10.1007/s00213-023-06390-y>
- Copeland, C. S., Rice, K., Rock, K. L., Hudson, S., Streete, P., Lawson, A. J., Couchman, L., Holland, A., Morley, S., 2024. Broad evidence of xylazine in the UK illicit drug market beyond heroin supplies: Triangulating from toxicology, drug testing and law enforcement. *Addiction*. 119. <https://doi.org/10.1111/add.16466>

Delcher, C., Quesinberry, D., Torabi, S., Berry, S., Keck, J. W., Rani, A., Subedi, B., 2024.

Wastewater surveillance for xylazine in Kentucky. *AJPM Focus*. 3, (3), 100203.

<https://doi.org/10.1016/j.focus.2024.100203>

D’Orazio, J., Nelson, L., Perrone, J., Wightman, R., Haroz, R., 2023. Xylazine adulteration of the heroin–fentanyl drug supply: A narrative review. *Ann Intern Med*. 176 (10).

<https://doi.org/10.7326/M23-2001>

Friedman, J., Montero, F., Bourgois, P., Wahbi, R., Dye, D., Goodman-Meza, D., Shover, C.,

2022. Xylazine spreads across the US: A growing component of the increasingly

synthetic and polysubstance overdose crisis. *Drug Alcohol Depend*. 233, 109380. doi:

[10.1016/j.drugalcdep.2022.109380](https://doi.org/10.1016/j.drugalcdep.2022.109380)

Friedman, J. R., Gonzalez Montoya, A., Ruiz, C., González Tejada, M. A., Segovia, L. A.,

Godvin, M. E., Sisco, E., Pyfrom, E., Appley, M., Shover, C., Pacheco Bufanda, L., 2024.

The detection of xylazine in Tijuana, Mexico: Triangulating drug checking and clinical

urine testing data. *medRxiv [preprint]*. <https://doi.org/10.1101/2024.08.19.24312273>

German, D., Genberg, B., Sugarman, O., Saloner, B., Sawyer, A., Glick, J. L., Gribbin, M.,

Flynn, C., 2024. Reported xylazine exposure highly associated with overdose outcomes

in a rapid community assessment among people who inject drugs in Baltimore. *Harm*

Reduct J. 21 (18). <https://doi.org/10.1186/s12954-024-00940-z>

Gupta, R., Holtgrave, D. R., Ashburn, M. A., 2023. Xylazine—medical and public health

imperatives. *N Engl J Med*. 388 (24). doi: [10.1056/NEJMp2303120](https://doi.org/10.1056/NEJMp2303120)

Hoffman, R. S., 2023. Closing the xylazine knowledge gap. *Clin Toxicol (Phila)*. 61 (12).

<https://doi.org/10.1080/15563650.2023.2294619>

- Holmes, L. M., Rishworth, A., King, B. H., 2022. Disparities in opioid overdose survival and naloxone administration in Pennsylvania. *Drug Alcohol Depend.* 238, 109555.
<https://doi.org/10.1016/j.drugalcdep.2022.109555>
- Johnson, J., Pizzicato, L., Johnson, C., Viner, K., 2021. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019. *Inj Prev.* 27 (4).
doi:10.1136/injuryprev-2020-043968
- Kariisa, M., O'Donnell, J., Kumar, S., Mattson, C. L., Goldberger, B. A., 2023. Illicitly Manufactured Fentanyl–Involved Overdose Deaths with Detected Xylazine—United States, January 2019–June 2022. *MMWR Morb Mortal Wkly Rep.* 72.
<http://dx.doi.org/10.15585/mmwr.mm7226a4>
- Korona-Bailey, J., Onyango, E., Hall, K. F., Jayasundara, J., Mukhopadhyay, S., 2023. Xylazine-involved fatal and nonfatal drug overdoses in Tennessee from 2019 to 2022. *JAMA Netw Open.* 6 (7). doi:10.1001/jamanetworkopen.2023.24001
- Love, J. S., Levine, M., Aldy, K., Brent, J., Krotulski, A. J., Logan, B. K., Vargas-Torres, C., Walton, S. E., Amaducci, A., Calello, D., Hendrickson, R., Hughes, A., Kurt, A., Judge, B., Pizon, A., Schwarz, E., Shulman, J., Wiegand, T., Wax, P., Manini, A. F., 2023. Opioid overdoses involving xylazine in emergency department patients: a multicenter study. *Clin Toxicol (Phila).* 61 (3). <https://doi.org/10.1080/15563650.2022.2159427>
- Thomas, C., Mondal, A., Levitas, M., Widman, C., Lemberg, B., 2024. Trends in tranquilizer prevalence of xylazine in oral fluid toxicology in Michigan, Ohio, and Indiana. *Research Square* [preprint]. <https://doi.org/10.21203/rs.3.rs-4669492/v1>

Pennsylvania State Police., 2024. Overdose Information Network Data CY January 2018-Current Monthly County State Police. https://data.pa.gov/Opioid-Related/Overdose-Information-Network-Data-CY-January-2018-hbkk-dwy3/about_data

Sibbesen, J., Abate, M. A., Dai, Z., Smith, G. S., Lundstrom, E., Kraner, J. C., Mock, A. R., 2023. Characteristics of xylazine-related deaths in West Virginia—Xylazine-related deaths. *Am J Addict.* 32 (3). doi: 10.1111/ajad.13365

Spencer, M. R., Cisewski, J. A., Warner, M., Garnett, M. F., 2023. Drug overdose deaths involving xylazine: United States, 2018–2021. *Vital Statistics Rapid Release*; no 30. <https://dx.doi.org/10.15620/cdc:129519>

Thompson, E., Tardif, J., Ujeneza, M., Badea, A., Green, T. C., McKee, H., McKenzie, M., Park, J. N., 2024. Pilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods. *Drug Alcohol Depend Rep.* 11, 100241. <https://doi.org/10.1016/j.dadr.2024.100241>

Wu, P. E., Austin, E., 2024. Xylazine in the illicit opioid supply. *CMAJ.* 196 (4). doi: <https://doi.org/10.1503/cmaj.231603>

Zagorski, C. M., Hosey, R. A., Moraff, C., Ferguson, A., Figgatt, M., Aronowitz, S., Stahl, N. E., Hill, L. G., McElligott, Z., Dasgupta, N., 2023. Reducing the harms of xylazine: Clinical approaches, research deficits, and public health context. *Harm Reduct J.* 20 (141). <https://doi.org/10.1186/s12954-023-00879-7>

Zhu, D. T., 2023. Public health impact and harm reduction implications of xylazine-involved overdoses: A narrative review. *Harm Reduct J.* 20, (131). <https://doi.org/10.1186/s12954-023-00867-x>


Table 1. Demographic characteristics reported in suspected overdose events involving fentanyl and xylazine versus fentanyl and no xylazine, as recorded in the Pennsylvania Overdose Information Network, 2018-2024.

	Fentanyl & Xylazine n=95 %	Fentanyl, no Xylazine n=10,531 %	P value [§]
Age, years			0.100
0-9	0.0	0.3	
10-19	0.0	1.4	
20-29	13.7	23.8	
30-39	40.0	38.6	
40-49	30.5	20.5	
50-59	11.6	10.6	
60-69	3.2	4.3	
70+	1.1	0.4	
Gender			0.709
Man	69.5	71.4	
Woman	30.5	28.4	
Unknown	0.0	0.2	
Race/ethnicity			0.234
NH White	82.1	80.7	
NH Black	7.4	8.9	
Hispanic	6.3	6.1	
NH AI/AN	1.1	0.1	
NH Asian	0.0	0.2	
Unknown	3.2	4.0	

Note. Data from the Pennsylvania State Police's Overdose Information Network, January 2018 through July 15, 2024, not including Philadelphia County. [§]P values calculated based on Fisher's Exact Tests. *Abbreviations:* NH, Non-Hispanic; AI/AN, American Indian/Alaska Native.

XYLAZINE-FENTANYL OVERDOSE REPORTS

Figure 1. Characteristics of suspected overdose events involving fentanyl and xylazine versus fentanyl and no xylazine, as recorded in the Pennsylvania Overdose Information Network,[†] 2018-2024.



Notes. Total number of fentanyl-involved overdoses = 10,626 (95 with xylazine also recorded and 10,531 without xylazine recorded).
[†]Data are from January 2018 through July 15, 2024 and do not include Philadelphia county. P values calculated based on Fisher's Exact tests for associations between fentanyl/xylazine versus fentanyl/no xylazine and each characteristic examined: Heroin, $p < 0.001$; Carfentanil, $p < 0.001$; Other synthetic opioid/fentanyl analog, $p < 0.001$; Pharmaceutical opioid, $p = 1.000$; Methamphetamine, $p < 0.001$; Cocaine/crack, $p < 0.364$; Benzodiazepines, $p = 0.022$; Alcohol, $p = 0.094$; Naloxone administered, $p < 0.001$; survived overdose, $p < 0.001$. *Abbreviations.* Oth. Syn. Opi., other synthetic opioids/fentanyl analogs; Pharm. Opi., pharmaceutical opioid; Methamphet., methamphetamine; Benzo., Benzodiazepine; Unk., unknown.

Table 2. Results of binomial logistic regression analysis predicting: A) naloxone administration, or B) overdose survival, based on xylazine involvement and selected covariates, among suspected fentanyl overdoses reported in the Pennsylvania Overdose Information Network,[†] 2018-2024.

	Outcome A: Naloxone Administration <i>n</i> =10,188	Outcome B: Overdose Survival <i>n</i> =9,790
	AOR [95% CI]	AOR [95% CI]
Xylazine co-involved	0.35*** [0.23-0.56]	0.21*** [0.13-0.35]
Age, years		
0-9	0.90 [0.37-2.16]	1.90 [0.61-5.90]
10-19	1.37 [0.91-2.06]	1.23 [0.80-1.87]
20-29	1.13* [1.01-1.27]	1.30*** [1.14-1.48]
30-39	1.00 [reference]	1.00 [reference]
40-49	0.86* [0.76-0.97]	0.74*** [0.66-0.85]
50-59	0.76*** [0.66-0.89]	0.67*** [0.57-0.78]
60-69	0.70** [0.56-0.87]	0.51*** [0.41-0.64]
70+	0.91 [0.45-1.84]	1.54 [0.62-3.79]
Gender		
Man	1.00 [reference]	1.00 [reference]
Woman	1.01 [0.92-1.11]	1.15* [1.03-1.28]
Race/ethnicity		
NH White	1.00 [reference]	1.00 [reference]
NH Black	1.44*** [1.22-1.70]	1.12 [0.94-1.34]
Hispanic	1.70*** [1.38-2.08]	1.31* [1.06-1.63]
NH AI/AN	0.27 [0.05-1.55]	0.25 [0.04-1.49]
NH Asian	1.10 [0.44-2.74]	0.76 [0.28-2.03]
Other drugs co-involved		
Heroin	1.30*** [1.17-1.44]	1.46*** [1.30-1.63]
Carfentanil	0.94 [0.69-1.28]	0.90 [0.65-1.24]
Other synthetic opioid/fentanyl analog	1.13 [0.95-1.35]	0.98 [0.82-1.18]
Pharmaceutical opioids	0.96 [0.74-1.25]	1.06 [0.80-1.42]
Methamphetamine	0.50*** [0.43-0.59]	0.37*** [0.31-0.44]
Cocaine/crack	0.50*** [0.43-0.58]	0.42*** [0.36-0.49]
Benzodiazepines	0.65** [0.49-0.86]	0.46*** [0.34-0.61]
Alcohol	0.90 [0.68-1.18]	0.67** [0.50-0.89]
County fixed effects	Yes	Yes
Year fixed effects	Yes	Yes
	AME [95% CI]	AME [95% CI]
Average Marginal Effect (AME), xylazine co-involvement, [95% CI]	-0.21*** [-0.30, -0.12]	-0.28*** [-0.36, -0.19]

Note. Survival denotes whether the individual survived the overdose incident. Naloxone administration denotes if naloxone was administered to the individual who overdosed. [†]Data are from January 2018 through July 15, 2024 and do not include Philadelphia county. Average Marginal Effects denote the proportional change in naloxone administration or overdose survival, respectively, when xylazine changes from not involved to involved in the overdose. Estimates in bold denote statistical significance (two-tailed): **p* < .05, ***p* < .01, ****p* < .001. *Abbreviations:* NH, Non-Hispanic; AI/AN, American Indian/Alaska Native; AOR, adjusted odds ratio; CI, confidence interval.

Table 3. Sensitivity analyses changing the sample to 1) any opioid or 2) the years 2022-2024, predicting A) naloxone administration, or B) overdose survival, based on xylazine involvement and selected covariates, among suspected opioid or fentanyl overdoses reported in the Pennsylvania Overdose Information Network.

	1. Overdoses Involving Any Opioid, 2018-2024 ^a		2. Fentanyl Overdoses, 2022-2024 ^a	
	Outcome A: Naloxone Administration <i>n</i> =24,512	Outcome B: Overdose Survival <i>n</i> =23,451	Outcome A: Naloxone Administration <i>n</i> =5,389	Outcome B: Overdose Survival <i>n</i> =5,185
	AOR [95% CI]	AOR [95% CI]	AOR [95% CI]	AOR [95% CI]
Xylazine involved	0.39*** [0.26-0.60]	0.19*** [0.12-0.31]	0.35*** [0.22-0.56]	0.22*** [0.13-0.37]
	AME [95% CI]	AME [95% CI]	AME [95% CI]	AME [95% CI]
Average Marginal Effect (AME), xylazine [95% CI]	-0.18*** [-0.26, -0.10]	-0.24*** [-0.31, -0.17]	-0.20*** [-0.29, -0.11]	-0.24*** [-0.32, -0.16]

Note. Survival denotes if the individual survived the overdose incident. Naloxone administration denotes if naloxone was administered to the individual who overdosed. Each regression model includes the following covariates: age, gender, race/ethnicity, drugs co-involved in the overdose (heroin, carfentanil, other synthetic opioid/fentanyl analog, pharmaceutical opioids, methamphetamine, cocaine/crack, benzodiazepines, and alcohol), and county- and year-fixed effects. ^aThrough July 15, 2024. Average Marginal Effects denote the proportional change in the outcome when xylazine changes from not involved to involved in the overdose. Estimates in bold denote statistical significance (two-tailed): **p* < .05, ***p* < .01, ****p* < .001. *Abbreviations:* AOR, adjusted odds ratio; CI, confidence interval.

Supplemental Table S1: Steps taken to identify unique records in the Overdose Information Network (ODIN) dataset and merge data on multiple drugs suspected to be involved in each overdose.

Step	Rationale/Details
Use ODIN “victim ID” number to identify unique “victims” within any given overdose incident reported	Some overdose events with the same ODIN “incident ID” include different persons (with different “victim ID” numbers) who suffered an overdose together.
Examine records with the same “victim ID” number to determine whether they all correspond to the same “incident ID” and date/time	<p>Records with the same “victim ID” but different “incident ID” and date/time would indicate the same person experiencing different overdose incidents at different times recorded in the ODIN.</p> <p>No records with the same “victim ID” but different “incident IDs” were located, suggesting that any repeat overdoses in the same victim were not identifiable due to assignment of a new victim ID each incident.</p>
Examine and compare the study measures (suspected drug, gender, age, race, ethnicity, county of occurrence, year, suspected drug, naloxone administration, and survival outcome) between records with the same victim ID/incident ID combination	<p>The ODIN includes multiple records with the same victim ID/incident ID combination.</p> <p>Examination of such multiple records revealed that the gender, age, race, ethnicity, county of occurrence, date/time, naloxone administration, and survival outcome were consistent/the same between all records with the same victim ID/incident ID combination.</p> <p>In contrast, the “suspected drug” field differed between multiple records.</p>
Merge records by victim ID	<p>Each record in ODIN can accommodate only one drug type due to only one “suspected drug” field available in each record. Thus multiple records for the same victim and incident are used to reflect multiple drug types suspected to be involved in any given person’s overdose incident.</p> <p>Merging based on victim ID (since there were no instances of the same victim ID with different incident IDs) allows us to maintain only one unique record for each victim while maintaining multiple fields for the “suspected drugs.”</p>

Supplemental Table S2. Number of suspected overdose events involving fentanyl and xylazine versus fentanyl and no xylazine, by county and year, as recorded in the Pennsylvania Overdose Information Network, 2018-2024.

	Fentanyl & Xylazine (n=95) Number	Fentanyl, no Xylazine (n=10,531) Number
Year of overdose		
2018	0	796
2019	0	1,100
2020	0	1,510
2021	2	1,593
2022	12	1,637
2023	51	2,862
2024 (partial year)	30	1,033
County where overdose occurred		
Adams	0	71
Allegheny	15	1,167
Armstrong	0	97
Beaver	0	134
Bedford	0	40
Berks	1	168
Blair	2	121
Bradford	0	14
Bucks	2	389
Butler	2	117
Cambria	2	130
Carbon	2	167
Centre	1	40
Chester	5	268
Clarion	0	22
Clearfield	4	58
Clinton	0	7
Columbia	2	143
Crawford	1	62
Cumberland	5	184
Dauphin	5	384
Delaware	3	190
Elk	1	64
Erie	1	933
Fayette	3	129
Forest	0	3
Franklin	3	157
Fulton	0	12
Greene	0	8
Huntingdon	2	27
Indiana	1	89
Jefferson	1	18
Juniata	0	7
Lackawanna	2	120
Lancaster	1	319
Lawrence	0	50
Lebanon	0	159
Lehigh	2	78
Luzerne	1	662
Lycoming	1	101

XYLAZINE-FENTANYL OVERDOSE REPORTS

21

McKean	0	22
Mercer	1	100
Mifflin	0	28
Monroe	1	228
Montgomery	6	968
Montour	0	21
Northampton	0	146
Northumberland	0	76
Perry	0	68
Pike	0	47
Potter	0	2
Schuylkill	0	200
Snyder	1	18
Somerset	2	58
Sullivan	0	3
Susquehanna	1	27
Tioga	0	42
Union	1	13
Venango	3	35
Warren	0	12
Washington	2	171
Wayne	0	20
Westmoreland	5	383
Wyoming	0	16
York	1	918

Note. Data from the Pennsylvania State Police's Overdose Information Network, January 2018 through July 15, 2024; not including Philadelphia County. As reported by Pennsylvania's criminal justice agencies and third-party first-responding organizations (e.g., EMS, Fire, Medical Staff) that voluntarily entered these data.

Supplemental Table S3. Drug co-involvement, naloxone administration, and survival in suspected overdose events involving fentanyl and xylazine versus fentanyl and no xylazine, as recorded in the Pennsylvania Overdose Information Network, 2018-2024.

	Fentanyl & Xylazine n=95 %	Fentanyl, no Xylazine n=10,531 %	P value [§]
Suspected drug involved in the overdose¹:			
Heroin	44.2	67.6	<0.001
Carfentanil	11.6	2.2	<0.001
Other synthetic opioid/fentanyl analog	20.0	7.6	<0.001
Pharmaceutical opioid	2.1	3.0	1.000
Methamphetamine	21.1	6.9	<0.001
Cocaine/crack	11.6	8.9	0.365
Benzodiazepines	6.3	2.3	0.022
Alcohol	5.3	2.5	0.090
Naloxone administered?			
Yes	41.1	67.5	
No	59.0	32.5	
Survived?			
Yes	34.7	68.3	<0.001
No	62.1	27.7	
Unknown	3.2	4.1	

Note. Data from the Pennsylvania State Police's Overdose Information Network, January 2018 through July 15, 2024, not including Philadelphia County. ¹As reported by Pennsylvania's criminal justice agencies and third-party first-responding organizations (e.g., EMS, Fire, Medical Staff) that voluntarily entered these data. [§]P values calculated based on Fisher's Exact Tests. *Abbreviations:* NH, Non-Hispanic; AI/AN, American Indian/Alaska Native.